
Fabrizio Ceci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9120954/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Longâ€Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. Journal of the American Heart Association, 2021, 10, e018932.	1.6	24

 $_2$ DNA Methylation Patterns Correlate with the Expression of SCNN1A, SCNN1B, and SCNN1G (Epithelial) Tj ETQq0 $_{1.8}^{00}$ rgBT /Overlock 10

3	Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. Journal of Clinical Lipidology, 2021, 15, 822-831.	0.6	7
4	Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2027-2035.	1.1	11
5	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines, 2020, 8, 625.	1.4	21
6	Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort. Expert Review of Anti-Infective Therapy, 2020, 18, 485-492.	2.0	4
7	Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2531-2541.	1.1	39
8	Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity. Pediatric Research, 2019, 85, 671-677.	1.1	27
9	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Scientific Reports, 2018, 8, 3702.	1.6	59
10	Severity of OSAS, CPAP and cardiovascular events: A followâ€up study. European Journal of Clinical Investigation, 2018, 48, e12908.	1.7	31
11	Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 143-149.	1.1	38
12	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage. Atherosclerosis, 2017, 257, 232-239.	0.4	39
13	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. American Journal of Gastroenterology, 2017, 112, 1832-1839.	0.2	109
14	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. Internal and Emergency Medicine, 2017, 12, 1159-1165.	1.0	16
15	Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: comparison with dual X-ray absorptiometry. HIV/AIDS - Research and Palliative Care, 2016, 8, 109.	0.4	6
16	Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. Journal of Lipid Research, 2016, 57, 1097-1107.	2.0	48
17	Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects. PLoS ONE, 2015, 10, e0120099.	1.1	11
18	Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach. Atherosclerosis, 2015, 242, 618-624.	0.4	18

FABRIZIO CECI

#	Article	IF	CITATIONS
19	Functional and morphological vascular changes in subjects with familial combined hypolipidemia: An exploratory analysis. International Journal of Cardiology, 2013, 168, 4375-4378.	0.8	15
20	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. Journal of Lipid Research, 2013, 54, 3481-3490.	2.0	76
21	Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1706-1713.	1.1	141
22	A template for mutational data analysis of the CFTR gene. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1447-51.	1.4	14
23	Fibrinogen metabolism in the lungs. Metabolism: Clinical and Experimental, 2005, 54, 271-274.	1.5	4
24	Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia. American Journal of Medicine, 2004, 117, 803-804.	0.6	14
25	Effects of different oxidizing agents on neutral amino acid transport systems in isolated bovine brain microvessels. Neurochemistry International, 2002, 41, 29-36.	1.9	3
26	Inhibitory effect of somatostatin on neutral amino acid transport in isolated brain microvessels. Journal of Neurochemistry, 2001, 78, 349-357.	2.1	2
27	Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis, 1999, 147, 249-252.	0.4	44
28	Plasma tryptophan and anorexia in human cancer. European Journal of Cancer & Clinical Oncology, 1986, 22, 89-95.	0.9	65